how many people are taking glp 1 drugs GLP-1 Market Size to Hit USD 132.79 Bn by 2035 GLP-1 Drugs Drop More Than

Bridging the gap between diabetes and cardiovascular disease: a comparative review of different glucagon-like peptide-1 (GLP-1) agonists: efficacy, safety, and patient outcomes

doi: 10.1023/A:1018863716749 160 SchirraJHouckPWankUArnoldRGkeBKatschinskiM

This is the not-so-secret secret, Collingwood says

Mo X, Shen L, Cheng R, Wang P, Wen L, Sun Y, et al

88 The pregnancy rate per embryo transfer rose to 85.7%, and the overall pregnancy rate reached 69% in the combination group, while it reached values of 28.6% and 35.7%, respectively, in the metformin group 88 (Figure 3(d))

Survodutide, a glucagon/GLP-1 dual agonist, met its primary endpoint of histological improvement in MASH at 48 weeks and also demonstrated a statistically significant improvement in fibrosis, a secondary endpoint